BR112019027398A2 - formas de dosagem orais de liberação controlada gastrorresistente - Google Patents

formas de dosagem orais de liberação controlada gastrorresistente Download PDF

Info

Publication number
BR112019027398A2
BR112019027398A2 BR112019027398-0A BR112019027398A BR112019027398A2 BR 112019027398 A2 BR112019027398 A2 BR 112019027398A2 BR 112019027398 A BR112019027398 A BR 112019027398A BR 112019027398 A2 BR112019027398 A2 BR 112019027398A2
Authority
BR
Brazil
Prior art keywords
dosage form
compound
controlled release
gastro
fact
Prior art date
Application number
BR112019027398-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Emmanuelle Georgi
Jay SAOUD
Remy Luthringer
Sandra Werner
Nadine Noel
Original Assignee
Minerva Neurosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62904624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112019027398(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Minerva Neurosciences, Inc. filed Critical Minerva Neurosciences, Inc.
Publication of BR112019027398A2 publication Critical patent/BR112019027398A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112019027398-0A 2017-06-21 2018-06-21 formas de dosagem orais de liberação controlada gastrorresistente BR112019027398A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762523204P 2017-06-21 2017-06-21
US62/523,204 2017-06-21
PCT/US2018/038853 WO2018237207A1 (en) 2017-06-21 2018-06-21 GESTRO-RESISTANT ORAL DOSAGE FORMS WITH CONTROLLED RELEASE

Publications (1)

Publication Number Publication Date
BR112019027398A2 true BR112019027398A2 (pt) 2020-07-07

Family

ID=62904624

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019027398-0A BR112019027398A2 (pt) 2017-06-21 2018-06-21 formas de dosagem orais de liberação controlada gastrorresistente

Country Status (16)

Country Link
US (3) US11464744B2 (https=)
EP (1) EP3641732A1 (https=)
JP (3) JP2020525436A (https=)
CN (1) CN111511353A (https=)
AU (2) AU2018290287B2 (https=)
BR (1) BR112019027398A2 (https=)
CA (1) CA3067031A1 (https=)
CL (1) CL2019003743A1 (https=)
CO (1) CO2019014496A2 (https=)
IL (3) IL308650B2 (https=)
MX (1) MX2023002994A (https=)
NZ (1) NZ760127A (https=)
PE (1) PE20200732A1 (https=)
UA (1) UA127349C2 (https=)
WO (1) WO2018237207A1 (https=)
ZA (1) ZA202409847B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2910528T3 (es) 2014-12-02 2022-05-12 Minerva Neurosciences Inc Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia
IL308650B2 (en) 2017-06-21 2025-08-01 Minerva Neurosciences Inc Gastro-resistant controlled release oral dosage forms
KR102886241B1 (ko) 2018-08-21 2025-11-14 미쓰비시 타나베 파마 코퍼레이션 음성 증상 및 장애를 치료하고, 신경가소성을 증가시키고, 신경보호를 촉진시키기 위한 롤루페리돈의 용도
IT201800011125A1 (it) * 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico
JP2025505261A (ja) 2022-02-14 2025-02-21 ミネルヴァ ニューロサイエンシズ，インコーポレーテッド 統合失調症患者における再発の予防におけるロルペリドンの使用
WO2025090588A1 (en) 2023-10-24 2025-05-01 Minerva Neurosciences, Inc. Roluperidone for the treatment of lysosomal storage disorders and their symptoms

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325063B1 (en) 1988-01-21 1994-03-09 Merrell Dow Pharmaceuticals Inc. Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
EP0497843A4 (en) 1989-10-27 1992-09-23 The Du Pont Merck Pharmaceutical Company (n-phthalimidoalkyl) piperidines
NZ251610A (en) 1992-04-23 1996-02-27 Merrell Dow Pharma 4-imidomethyl-1-(2-phenyl-2-oxoethyl)piperidine derivatives and pharmaceutical compositions
NZ521576A (en) 2000-02-29 2005-06-24 Mitsubishi Pharma Corp Novel cyclic amide derivatives
AU2357202A (en) 2000-09-29 2002-04-08 Solvay Pharm Bv Ion-strength independent sustained release pharmaceutical formulation
TW200517106A (en) 2003-10-29 2005-06-01 Wyeth Corp Sustained release pharmaceutical compositions
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
TW200616608A (en) 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
PE20061490A1 (es) 2005-06-06 2007-02-09 Merck Sharp & Dohme Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
US20090088449A1 (en) 2006-02-07 2009-04-02 Mitsubishi Tanabe Pharma Corporation 4-acylaminopyridine derivative mediated neurogenesis
CA2569776A1 (en) 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
KR20080089279A (ko) 2007-03-30 2008-10-06 미쓰비시 타나베 파마 코퍼레이션 우울증의 예방 및/또는 치료제
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
EP2246331A1 (en) 2009-04-24 2010-11-03 Westfälische Wilhelms-Universität Münster NR2B-selective NMDA-receptor antagonists
ES2649112T3 (es) * 2009-05-18 2018-01-10 Sigmoid Pharma Limited Composición que comprende gotas de aceite
AR081935A1 (es) 2010-06-16 2012-10-31 Teijin Pharma Ltd Tableta con nucleo recubierto de liberacion controlada
WO2012012542A1 (en) 2010-07-20 2012-01-26 Cyrenaic Pharmaceuticals, Inc. Methods of use of cyclic amide derivatives to treat schizophrenia
US8937900B2 (en) 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
CN103108548A (zh) 2010-07-20 2013-05-15 昔勒尼药品公司 使用环酰胺衍生物治疗σ受体介导的病症的方法
US20120040008A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
EP2468264A1 (en) * 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
KR20140045925A (ko) 2011-03-17 2014-04-17 루핀 리미티드 선택적 세로토닌 재흡수 억제제의 방출조절형 약제학적 조성물
CN104023725B (zh) * 2011-08-16 2019-04-26 卡迪欧拉有限公司 控释制剂
AU2014239883B2 (en) * 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
CN104586771B (zh) * 2013-10-30 2018-01-16 广州朗圣药业有限公司 一种盐酸坦洛新缓释微丸制剂
CN106687462A (zh) 2014-04-30 2017-05-17 因赛特公司 Jak1抑制剂的制备方法以及其新形式
EP3144308B1 (en) 2014-05-16 2020-06-24 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
WO2015191554A1 (en) 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
RU2697851C2 (ru) * 2014-08-13 2019-08-21 Седарс-Синаи Медикал Сентер Антиметаногенные композиции и их применение
ES2910528T3 (es) 2014-12-02 2022-05-12 Minerva Neurosciences Inc Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia
JP6855469B2 (ja) * 2015-10-16 2021-04-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 消化器標的療法のための処方物を調製するための工程
SG11201810358YA (en) 2016-05-25 2018-12-28 Mitsubishi Tanabe Pharma Corp Compositions and methods for treating negative symptoms in non-schizophrenic patients
IL308650B2 (en) 2017-06-21 2025-08-01 Minerva Neurosciences Inc Gastro-resistant controlled release oral dosage forms
KR102886241B1 (ko) 2018-08-21 2025-11-14 미쓰비시 타나베 파마 코퍼레이션 음성 증상 및 장애를 치료하고, 신경가소성을 증가시키고, 신경보호를 촉진시키기 위한 롤루페리돈의 용도
EP3990113A1 (en) 2019-06-28 2022-05-04 Teva Czech Industries s.r.o. Solid state forms of roluperidone and salts thereof
JP2025505261A (ja) 2022-02-14 2025-02-21 ミネルヴァ ニューロサイエンシズ，インコーポレーテッド 統合失調症患者における再発の予防におけるロルペリドンの使用

Also Published As

Publication number Publication date
NZ760127A (en) 2026-02-27
CA3067031A1 (en) 2018-12-27
IL271606B1 (en) 2024-01-01
JP2025134828A (ja) 2025-09-17
WO2018237207A1 (en) 2018-12-27
EP3641732A1 (en) 2020-04-29
CN111511353A (zh) 2020-08-07
US20220401368A1 (en) 2022-12-22
IL271606B2 (en) 2024-05-01
UA127349C2 (uk) 2023-07-26
US12048768B2 (en) 2024-07-30
JP2023175778A (ja) 2023-12-12
AU2024219717A1 (en) 2024-10-03
AU2018290287B2 (en) 2024-06-13
RU2020102015A3 (https=) 2021-10-04
PE20200732A1 (es) 2020-07-23
US20250009665A1 (en) 2025-01-09
US11464744B2 (en) 2022-10-11
US20190038561A1 (en) 2019-02-07
CO2019014496A2 (es) 2020-04-01
IL271606A (en) 2020-02-27
AU2018290287A1 (en) 2020-01-16
IL308650B1 (en) 2025-04-01
ZA202409847B (en) 2025-09-25
IL319156A (en) 2025-04-01
IL308650A (en) 2024-01-01
MX2023002994A (es) 2023-09-15
JP2020525436A (ja) 2020-08-27
CL2019003743A1 (es) 2020-07-03
RU2020102015A (ru) 2021-07-21
IL308650B2 (en) 2025-08-01

Similar Documents

Publication Publication Date Title
US12048768B2 (en) Gastro-resistant controlled release oral dosage forms
RU2335280C2 (ru) Таблетки тамзулосина с модифицированным высвобождением
US20150157575A1 (en) Pharmaceutical Formulations Comprising Vilazodone
US20160256398A1 (en) Compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
JP5879359B2 (ja) クエン酸及び重炭酸塩を含んでなる医薬組成物、並びにシスチン尿症を治療するためのこれらの使用
Di Giorgio et al. Treatment with an ileal bile acid transporter inhibitor in patients with TJP2 deficiency
US9849097B2 (en) Dosage forms containing terbutaline sulphate
Zhao et al. Initial treatment with a single capsule containing half-dose quadruple therapy vs standard-dose dual therapy in hypertensive patients (QUADUAL): Study protocol for a randomized, blinded, crossover trial
Gao et al. Investigation of human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (efavirenz)
RU2812901C2 (ru) Кишечнорастворимые лекарственные формы для перорального применения с контролируемым высвобождением
US20070053975A1 (en) Ramipril formulation
TWI841545B (zh) 耐胃性控制釋放經口劑型
Hodges et al. Pharmacoscintigraphy confirms consistent tamsulosin release from a novel triple-layered tablet
US20250367137A1 (en) Phloroglucinol Formulations And Methods Of Use
KR102817359B1 (ko) 나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 경구용 약학 제제
Sakurai et al. Evaluation for zero-order controlled release preparations of nifedipine tablet on dissolution test, together with cost benefit point of views
WO2026050513A1 (en) Tolebrutinib for multiple sclerosis
CN119499203A (zh) 一种盐酸二甲双胍肠溶片
Letsoalo Development and evaluation of a combination analgesic capsule
Chikkamath Design and Evaluation of Novel Drug Delivery System of a Proton Pump Inhibitor
oif Child MALPRACTICE Chronicle
BR112015022103B1 (pt) Composição farmacêutica para prevenir ou tratar uma doença cardiovascular e uma doença hiperlipidêmica, ou tratar sinergicamente hipertensão, e, método para preparar uma composição farmacêutica
WO2015080624A1 (ru) Таблетки - ретард с тримебутином

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.1 NA RPI NO 2874 DE 03/02/2026 POR TER SIDO INDEVIDA.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/06/2018, OBSERVADAS AS CONDICOES LEGAIS